EquitiesIndia.com

Healthcare · Drug Manufacturers - Specialty & Generic

Laurus Labs Ltd.

LAURUSLABS

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. In addition, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.

NSE: LAURUSLABSOfficial website ↗

Key metrics

Market Cap

₹59,309 cr

P/E Ratio

70.41x

P/B Ratio

13.26x

ROE

8.01%

ROCE

9.55%

Debt / Equity

0.62x

Net Margin

6.51%

Dividend Yield

15%

EPS

₹6.64

Period

FY2025

Shareholding pattern

As of Latest
Promoter: 32.16%FII: 43.20%Public: 24.64%

Deep-dive pages

Educational content — not investment adviceThis page presents publicly available information about Laurus Labs Ltd. for educational purposes only. EquitiesIndia.com is not a SEBI-registered Investment Adviser or Research Analyst. Nothing here constitutes investment advice, a recommendation to buy or sell any security, or a solicitation to transact. All financial data shown is sourced from public BSE/NSE filings and is at least 90 days old. Past performance is not indicative of future results. Please consult a SEBI-registered adviser before making any investment decision.